Haemonetics Co. (NYSE:HAE) CFO Willaim P. Burke sold 13,193 shares of the firm’s stock in a transaction on Tuesday, November 14th. The stock was sold at an average price of $54.04, for a total value of $712,949.72. Following the transaction, the chief financial officer now owns 27,227 shares in the company, valued at $1,471,347.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Haemonetics Co. (HAE) traded up $1.26 during mid-day trading on Thursday, reaching $57.32. The company’s stock had a trading volume of 476,577 shares, compared to its average volume of 349,197. The company has a debt-to-equity ratio of 0.22, a current ratio of 2.17 and a quick ratio of 1.51. The company has a market capitalization of $3,030.00, a PE ratio of 33.42, a price-to-earnings-growth ratio of 4.08 and a beta of 0.91. Haemonetics Co. has a 12 month low of $36.44 and a 12 month high of $57.66.

Haemonetics (NYSE:HAE) last posted its earnings results on Tuesday, November 7th. The medical instruments supplier reported $0.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.41 by $0.07. The company had revenue of $225.40 million for the quarter, compared to analysts’ expectations of $219.12 million. Haemonetics had a return on equity of 10.24% and a net margin of 8.92%. The firm’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same period last year, the business posted $0.38 earnings per share. analysts predict that Haemonetics Co. will post 1.7 EPS for the current fiscal year.

WARNING: “Haemonetics Co. (HAE) CFO Willaim P. Burke Sells 13,193 Shares” was published by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States and international copyright laws. The original version of this piece can be accessed at https://www.watchlistnews.com/haemonetics-co-hae-cfo-willaim-p-burke-sells-13193-shares/1708096.html.

Several equities analysts recently issued reports on the company. Morgan Stanley raised their price objective on Haemonetics from $43.00 to $51.00 and gave the stock an “equal weight” rating in a research note on Thursday, November 9th. Barrington Research raised their price objective on Haemonetics from $48.00 to $57.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 8th. Craig Hallum restated a “hold” rating and set a $50.00 price objective (up from $40.00) on shares of Haemonetics in a research note on Wednesday, November 8th. Zacks Investment Research cut Haemonetics from a “buy” rating to a “hold” rating in a research note on Tuesday. Finally, TheStreet upgraded Haemonetics from a “c” rating to a “b-” rating in a research note on Monday, August 7th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $51.33.

Hedge funds have recently bought and sold shares of the business. Shine Investment Advisory Services Inc. bought a new stake in Haemonetics in the second quarter valued at $132,000. Riverhead Capital Management LLC lifted its stake in Haemonetics by 79.3% in the second quarter. Riverhead Capital Management LLC now owns 3,407 shares of the medical instruments supplier’s stock valued at $135,000 after buying an additional 1,507 shares during the last quarter. Pacad Investment Ltd. bought a new stake in Haemonetics in the second quarter valued at $174,000. Shelton Capital Management bought a new stake in Haemonetics in the second quarter valued at $204,000. Finally, Cubist Systematic Strategies LLC bought a new stake in Haemonetics in the second quarter valued at $260,000.

About Haemonetics

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Receive News & Ratings for Haemonetics Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Co. and related companies with Analyst Ratings Network's FREE daily email newsletter.